RxDoctor Payments Data

Nauman Shahid, MD

Internal Medicine · Toledo, OHNPI 1396901245

Payments from drug & device makers

$857in general payments, 2019–2025

Across 30 payments — averaging $28.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$194
  • Medtronic$138
  • Merck$108
  • Covidien LP$75
  • AbbVie$48
  • Novartis$45
  • plus $250 from 11 others

What the payments were for

  • Food & beverage$80294%
  • Education$566%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$857 in reported general payments places this provider in the 70th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$182,685
Medicare patients
552
Services billed
1,831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide39$812,512
CalquenceAcalabrutinib Maleate47$705,422
RevlimidLenalidomide38$587,750
CabometyxCabozantinib S-Malate21$558,571
XtandiEnzalutamide32$467,035
Lenalidomide28$416,272
JakafiRuxolitinib Phosphate24$410,751
TagrissoOsimertinib Mesylate24$392,376
BrukinsaZanubrutinib13$189,821
Abiraterone Acetate70$184,432
EliquisApixaban134$128,080
Pazopanib Hcl15$69,534
XareltoRivaroxaban47$49,850
Exemestane14$9,314
Morphine Sulfate ErMorphine Sulfate26$8,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence, Tagrisso$15$1,097,79971 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$13$812,51239 claims
Bristol Myers SquibbRevlimid$12$587,75038 claims
Exelixis Inc.Cabometyx$15$558,57121 claims
Astellas Pharma US IncXtandi$14$467,03532 claims
PfizerEliquis$12$128,080134 claims
Johnson & JohnsonXarelto$41$49,85047 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →